ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Analysts Warm to JCI, Mosaic Takes a Hit

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Johnson Controls International leads today's upgrades. The building-tech firm saw its consensus rating revised upward, with the average analyst target price moving to $169.70 from $168.50. The upgrade signals growing confidence in its restructuring story.

DA Davidson initiated two financial-technology names. Tyler Technologies and Broadridge Financial Solutions both received fresh Buy ratings, with targets set at $460 and $214 respectively. Peter Heckmann at DA Davidson sees value in both government-software and financial-processing platforms.

The most notable downgrade came at Mosaic. UBS cut its target to $19 from $23, retaining a Hold. The fertiliser giant has faced persistent pressure from weaker potash and phosphate pricing, and UBS sees little near-term catalyst.

CF Industries got the opposite treatment. UBS raised its CF target to $134 from $123, keeping a Hold. The nitrogen-heavy business looks better positioned in the current crop-nutrient cycle.

Zoetis also got a UBS target lift to $85 from $80, again with a Hold rating maintained.

PayPal saw a small consensus target bump to $57.07. Corning went the other way, with the consensus target edging down to $187.

Centene rounds out the upgrades. The managed-care insurer's consensus target ticked up to $72, suggesting analysts see stability after a volatile stretch tied to Medicaid redetermination.

Stocks in this article

How this article was generated

Generated
28 Oct 2026, 04:21
Prompt version
v1.0
Data sources
Analyst consensusAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.